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feed additive for all animal species
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
DL-Selenomethionine  (DL-SeMet)  consists  of  40 %  selenium,  an  essential  trace  element.  DL-SeMet.  It  was 
tolerated by chickens for fattening at up to 1.5 mg selenium supplemented/kg feed; DL-SeMet is therefore safe 
for  chickens  for  fattening  provided  total  dietary  selenium  does  not  exceed  0.5  mg/kg  complete  feed;  this 
conclusion is extended to all animal species. Based on available toxicity studies and previous assessments of 
closely related compounds, it is concluded that selenium from DL-SeMet does not elicit any adverse effects not 
expected in a selenium compound. The use of DL-SeMet in animal nutrition is expected to result in a similar 
increase in selenium deposition in animal tissues/products as that resulting from other sources of SeMet. To 
ensure consumer safety from consumption of food originating from animals fed  DL-SeMet, dietary selenium 
supplementation from the additive should not exceed a maximum of 0.2 mg Se/kg complete feed. Although a 
DL-SeMet-containing additive did not release any measurable dust, the additive is considered as a hazard by 
inhalation, which requires protection measures for users since the additive is not the subject of authorisation, and 
selenium is highly toxic. The additive is not an irritant to skin and eyes and is not a dermal sensitiser. The use of 
DL-SeMet in feed does not pose an additional risk to the environment, compared with other sources of selenium 
for  which it  will substitute,  as long as the  maximum authorised content in  complete  feed is  not exceeded. 
Sufficient evidence is provided that DL-SeMet is an effective source of selenium in chickens for fattening. Since 
there are no fundamental differences between target animals in the metabolism of SeMet and its use for the 
specific biological functions of selenium, the FEEDAP Panel extends its conclusion on the efficacy of DL-SeMet 
to all animal species and categories. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of DL-selenomethionine (Mintrex
®Se) as feed additive for all animal species. 
DL-Selenomethionine (DL-SeMet) consists of 40 % selenium, an essential trace element. 
DL-SeMet was tolerated by chickens for fattening at up to 1.5 mg Se supplemented/kg feed; DL-SeMet 
is therefore safe for chickens for fattening provided total dietary selenium does not exceed 0.5 mg/kg 
complete feed. The FEEDAP Panel extends this conclusion to all animal species. 
Based  on  available  toxicity  studies  and  previous  assessments  of  closely  related  compounds,  the 
FEEDAP  Panel  concludes  that  selenium  from  DL-SeMet  does  not  elicit  any  adverse  effects  not 
expected in a selenium compound. The use of DL-SeMet in animal nutrition is expected to result in a 
similar increase in selenium deposition in animal tissues/products as that resulting from other sources 
of SeMet. To ensure consumer safety from consumption of food originating from animals fed  DL-
SeMet, dietary selenium supplementation from the additive should not exceed a maximum of 0.2 
mg/kg complete feed. 
Although  a  DL-SeMet-containing  additive  did  not  release  any  measurable  dust,  the  additive  is 
considered as a hazard by inhalation, which requires protection measures for users since the additive is 
not the subject of authorisation, and selenium is highly toxic. The additive is not an irritant to skin and 
eyes and is not a dermal sensitiser. 
The use of DL-SeMet in feed does not pose an additional risk to the environment, compared with other 
sources  of  selenium  for  which  it  will  substitute,  as  long  as  the  maximum  authorised  content  in 
complete feed is not exceeded. 
Sufficient  evidence is provided  that  DL-SeMet  is  an  effective  source  of  selenium  in  chickens for 
fattening. Since there are no fundamental differences between target animals in the metabolism of 
SeMet and its use for the specific biological functions of selenium, the FEEDAP Panel extends its 
conclusion on the efficacy of DL-SeMet to all animal species and categories. 
The FEEDAP Panel made some recommendations concerning the description and characterisation of 
the additive, and its use in premixtures only. DL-Selenomethionine for all species 
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BACKGROUND  
Regulation  (EC)  No  1831/2003
4  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The  European  Commission  received  a  request  from  the  company  Novus  Europe  SA/NV
5  for 
authorisation of  DL-selenomethionine  (Mintrex
®Se),  when  used  as  a  feed  additive  for  all  animal 
species (category: nutritional additives; functional group: compounds of trace elements) under the 
conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application  to  the  European  Food  Safety  Authority  (EFSA)  as  an  application  under  Article  4(1) 
(authorisation  of  a  feed  additive  or  new  use  of  a  feed  additive).
6  According to Article 8 of that  
Regulation, EFSA, after verifying the particulars and do cuments submitted by the applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 21 March 2013. 
Two forms of inorganic selenium, sodium selenite and sodium selenate, are authorised in the European 
Union (EU) as source of the essential trace element selenium, under Directive 70/524/EEC.
7
 Organic 
forms of selenium produced by Saccharomyces cerevisiae CNCM I-3060, S. cerevisiae NCYC R397 
and S. cerevisiae CNCM I-3399 are authorised in the EU as trace element under Regulation (EC) No 
1831/2003.
8,9,10  These latter authorisations have been granted following corresponding EFSA opinions 
(EFSA 2006a, 2006b, 2009a). Two additional opinions on the safety and efficacy of selenium in the 
form  of  organic  compounds  produced  by  the  selenium-enriched  yeast  S.  cerevisiae  NCYC  R645 
(EFSA, 2011a) and NCYC R646 (EFSA, 2012a) for all animal species were delivered by the FEEDAP 
Panel. An opinion on the safety and efficacy of Sel-Plex
® (organic form of selenium produced by 
Saccharomyces cerevisiae CNCM I-3060) when used as zootechnical feed additive was adopted by 
the FEEDAP Panel (EFSA, 2011b). Other opinions on the safety and efficacy of hydroxy-analogue of 
selenomethionine as feed additive for all species (EFSA FEEDAP Panel, 2013a) and on the safety and 
efficacy of L-selenomethionine as feed additive for all animal species (EFSA FEEDAP Panel, 2013b) 
have been delivered by the FEEDAP Panel. Following opinions of the FEEDAP Panel on organic 
selenium-based  additives,  the  EC  has  issued  two  Regulations
11  in which the supplementation of 
organic selenium in complete feed is limited to 0.2 mg Se/kg. 
TERMS OF REFERENCE  
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety  for  the  target  animal(s),  consumer,  user  and  the  environment  and  the  efficacy  of  DL-
selenomethionine (Mintrex
®Se), when used under the conditions described in Table 1. 
                                                       
4   Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
  in animal nutrition. OJ L 268, 18.10.2003, p. 29.  
5   Novus Europe SA/NV, Woluwe Atrium, Neerveld 101-103, 1200 Brussels, Belgium. 
6   EFSA Dossier reference: FAD-2012-0042. 
7   List of the authorised additives in feedingstuffs published in application of Article 9t (b) of Council Directive 70/524/EEC 
  concerning additives in feedingstuffs. OJ C 50, 25.2.2004, p.1. 
8  Commission Regulation (EC) No 1750/2006 of 27 November 2006 concerning the authorisation of selenomethionine as a 
  feed additive. OJ L 330, 28.11.2006, p.9. 
9  Commission Regulation (EC) No 634/2007 of 7 June 2007 concerning the authorisation of selenomethionine produced by 
  Saccharomyces cerevisiae NCYC R397 as a feed additive. OJ L 146, 08.06.2007, p.14. 
10   Commission Regulation (EC) No 900/2009 of 25 September 2009 concerning the authorisation of selenomethionine 
  produced by Saccharomyces cerevisiae CNCM I-3399 as a feed additive. OJ L 256, 29.09.2009, p.12. 
11 Commission Implementing Regulation (EU) No 427/2013; Commission Implementing Regulation (EU) No 445/2013. DL-Selenomethionine for all species 
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Table 1:  Description and conditions of use of the additive as proposed by the applicant  
Additive   DL-selenomethionine 
Registration number/EC 
No/No (if appropriate)  3b8.xx 
Category(-ies) of additive  Nutritional feed additive 
Functional group(s) of additive  Compounds of trace elements 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Preparation  of  DL-
selenomethionine (DL-SeMet) 
DL-SeMet 0.5% 
(5,000  mg  DL-
SeMet/kg 
supplying  2,000 
mg Se/kg) 
Complies with EU feed 
hygiene law 
HPLC-UV  for  DL-SeMet, 
ICP-MS for Se 
 
Trade name (if appropriate)  Mintrex® Se 
Name of the holder of 
authorisation (if appropriate)  Novus Europe SA/NV 
 
Conditions of use 
Species  or 
category  of 
animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  mg/kg of complete feedingstuffs 
All species and 
categories 
No 
maximum 
age 
No minimum content 
0.5  mg  Se/kg  feed  from 
all  sources  (endogenous 
and added) 
Not applicable 
 
Other provisions and additional requirements for the labelling 
Specific conditions or restrictions for 
use (if appropriate)  Store in a cool, dry place (< 25ºC), in closed, original packaging 
Specific conditions or restrictions for 
handling (if appropriate) 
Avoid  contact  with  eyes  or  skin.  Breathing  protection  during 
handling, safety glasses and gloves 
Post-market monitoring  
(if appropriate) 
As  per  EU  feed  hygiene  regulation:  traceability,  HACCP-based 
quality  control,  formal  product/service  complaints  procedure,  and 
product recall capability 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
Final feed (12% dry matter basis) should contain not more than 0.5 
mg Se/kg, from all sources (endogenous and added) 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
Not applicable  Not applicable  Not applicable  Not applicable DL-Selenomethionine for all species 
 
EFSA Journal 2014;12(2):3567  6 
ASSESSMENT 
1.  Introduction  
Several selenium compounds are authorised as feed additives in the EU. The total dietary selenium is 
limited to 0.5 mg/kg and the addition of organic selenium compounds to 0.2 mg Se/kg.
12 
The biological role of selenium, its deficiency and toxicity symptoms in farm animals were described 
in a previous opinion of the FEEDAP Panel (EFSA, 2006a). Selenium is a trace element  which is 
essential for vertebrates and   involved in a series o f vital metabolic functions (e.g. prevention of 
oxidative stress, proper thyroid function, maintenance of cellular redox status, immunocompetence, 
detoxification of heavy metals and xenobiotics). To the knowledge of the FEEDAP Panel, there is no 
additional relevant information that may lead to reconsideration of its previous opinion.  
Since the selenium content of grain and forages is generally  lower than animal requirements in most 
European countries, livestock is routinely supplied with extra dietary sele nium in order to avoid 
selenium deficiency. 
The FEEDAP Panel has recently adopted an opinion on  L-selenomethionine as feed additive for all 
animal species (EFSA FEEDAP Panel, 2013b). The EFSA‟s Panel on Food Additives and Nutrient 
Sources added to Food (EFSA, 2009b) delivered an opinion on L-selenomethionine for use in food 
supplements; L-selenomethionine is authorised by Commission Regulation (EC) No 1170/2009
13
 as 
mineral which may be used in the manufacture of food supplements.  
2.  Characterisation  
For compounds of trace elements, the element itself is considered the active substance. 
2.1.  Characterisation of the additive  
The  additive  is  intended  to  be  marketed  in  a  solid  form  with  a  composition  of  0.5 %  DL-
selenomethionine (DL-SeMet) and 99.5 % carrier, the latter corresponding, by specification, to 99 % 
calcium carbonate and 0.5 % mineral oil. The intended selenium concentration in the finished product 
is 2000 mg/kg.  
During the course of the assessment the applicant changed the formulation of the additive (the calcium 
carbonate with a changed granulometry). The data submitted by the applicant on this section, with the 
exception of the second set of data on particle size distribution and dusting potential, were derived 
from the additive as initially formulated. 
The analysis of five batches of the additive
14 showed a mean content of 5297 mg/kg of SeMet (range 
5155 5415) and 2146 mg Se/kg (range 2082 2192). The additive is a solid white to tan powder. It is 
practically insoluble in water  (0.013 g/L at 18 °C). The bulk density (three batches) is 1.55–1.60 
kg/L.
15  
Heavy metals, arsenic and dioxins and dioxin-like polychlorinated biphenyls (PCBs) were measured in 
three batches of the additive. The results per kg additive were: 0.98–1.13 mg lead, <0.5 mg cadmium, 
<0.02 mg mercury, < 0.50 0.52 mg arsenic,
16 0.09 0.39 ng PCDD/F-WHO-TEQ/kg, 0.029 0.142 ng 
                                                       
12   Commission Implementing Regulation (EU) No 427/2013; Commission Implementing Regulation (EU) No 445/2013. 
13   Commission Regulation (EC) No 1170/2009 of 30 November 2009 amending Directive 2002/46/EC of the European 
  Parliament and of Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as re gards 
  the lists of vitamin and minerals and their forms that can be added to foods, including food supplements. OJ L 314, 
  1.12.2009, p. 36. 
14   Technical Dossier/Section II /Annex_II_1_3_2. 
15   Technical Dossier/Section II /Annex_II_1_5_2. 
16 Technical Dossier/Section II/ Annex_II_1_4_2_2. DL-Selenomethionine for all species 
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dioxin-like PCBs-WHO-TEQ/kg and 0.119 0.535 ng for the sum of dioxins plus dioxin like PCBs.
17 
The cadmium, lead and arsenic contents in the additive, as well as dioxins and the sum of dioxins and 
dioxin-like PCBs were below the limits set in Directive 2002/32/EC.
18 The concentration of mercury is 
not of safety concern. The analysis of five batches of the additive for residual solvents resulted in a 
content of < 3 mg/kg additive;
19 this value is far below that indicated by the European Agency for the 
Evaluation of Medicinal Products   as concentration limits for  the relevant  single Class 2 solvents 
(EMEA, 2000). 
Microbial contamination was examined in three batches and was shown to be very low (aerobic plate 
count, 30°C: < 100 CFU/g; anaerobic count, 30 °C: < 10 colony-forming units (CFU)/g; coagulase-
positive  Staphylococci  counts  at  27 °C:  < 10  CFU/g;  Clostridium  perfringens,  yeasts,  moulds  and 
Enterobacteriaceae: < 10 CFU/g). Salmonella spp. were not detected in 25 g.
20 
Particle size was determined by laser diffraction in three lots. Ten percent of the particles (v/v) showed 
a diameter <  311 384  µm.
21  The dusting potential measured ( as determined using the  Stauber-
Heubach method) in the same three lots amounted to 0.110 –0.124  g/m
3.
22  The median particle 
diameter of the dust was 9   µm.
23  Upon request of EFSA, the applicant provided information  on 
particle size distribution and dusting potential  in other two batches of the additive. The data showed 
that 10 % of the particles (v/v) had a diameter < 549 565 µm;
24 a dusting potential in the same batches 
could not be detected.
25 These new data were derived from analysis in the modified formulation of the 
additive mentioned above, as well as the bulk density which was 1.49 kg/L.
26 
The FEEDAP Panel notes that the calcium carbonate used in the new formulation of the additive could 
have an impact on the product characterisation, notably on the impurities level. The applicant did not 
submit any new analyses performed with the new formulated additive, however he  stated that the 
manufacturer has in place an appropriate hazard analysis and critical control points (HACCP) system 
and  quality  control  procedures   to  guarantee  the  compliance  with  the  undesirable  substances 
legislation. 
2.2.  Characterisation of the DL-selenomethionine 
The compound of trace element in the additive is  DL-SeMet, the racemic mixture of the D and L 
enantiomers.  The  molecular  formula  is  C5H11NO2Se,  Chemical  Abstracts  Service  (CAS)  number 
2578-28-1, the International Union of Pure and Applied Chemistry (IUPAC) name is (RS2)-2-amino-
4-methylselenylbutanoic acid and it has a molecular weight of 196.11 g/mol. The theoretical selenium 
content is 40.26 %. The molecular structure of DL-SeMet is given in Figure 1. The melting point is 
267 269 °C; the boiling point is 320.8 °C. 
 
Figure 1:   SeMet molecular structure 
                                                       
17 Technical Dossier/Section II/ Annex_II_1_4_2_3. 
18 Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in 
  animal feed. OJ L 140, 30.5.2002, p. 10. 
19 Technical Dossier/Section II/ Annex_II_1_4_2_4 
20 Technical Dossier/Section II/ Annex_II_1_4_2_1. 
21   Technical Dossier/Section II /Annex_II_1_5_1. 
22 Technical Dossier/Section II/ Annex_II_1_5_4. 
23   Technical Dossier/Section II/ Annex_II_1_5_1. 
24   Technical Dossier/Supplementary information/Annex_II_1_5_5. 
25 Technical Dossier/ Supplementary information/Annex_II_1_5_8. 
26   Technical Dossier/Supplementary information/Annex_II_1_5_6. DL-Selenomethionine for all species 
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The purity of the DL-SeMet under assessment is specified as ≥ 97 %. In five batches of DL-SeMet 
analysed, purity was ≥ 99 %.
27 Analytical data for heavy metals and arsenic, dioxins and dioxin-like 
PCBs for the compound DL-SeMet were requested but not submitted. 
2.3.  Manufacturing process
28 
The  manufacturing  process  of  the  DL-SeMet  is  fully  described  in the technical  dossier.
29  For the 
manufacturing of the final additive, DL-SeMet is blended with calcium carbonate (99 %) and mineral 
oil (0.5 %).
30  
2.4.  Stability and homogeneity  
2.4.1.  Stability  
The shelf-life of the additive in metallised polyester bags  was tested in three lots under standard 
(25 °C, 60 % relative humidity (RH)) and accelerated conditions (40 °C, 75 % RH) for three and six 
months.
31 Recovery rates of SeMet (percentage of the initial value) after six months storage ranged 
from 97 to 100 % when stored under standard conditions, and from 93 to 100 % when stored under 
accelerated conditions. 
The stability of the additive was tested in a standard vitamin-trace elements premixture (with choline 
chloride) for chickens for fattening, supplemented with 150 mg DL-SeMet (60 mg Se) per kg; the 
samples of three lots were stored under standard conditions (25 °C, 60 % RH) up to six months.
32 One 
sample was frozen for 11 months before analysis, and will not be considered. Recovery of SeMet (two 
lots) after six months storage at 25 °C and 60 % RH ranged from 70 to 106 % of the expected value.  
The stability of the additive (three lots) in feedingstuffs was examined in a complete corn-soybean 
feed for chickens for fattening for three months. The additive was added via a premixture consisting of 
the basal feed to provide 0.75 mg  DL-SeMet/kg (0.3 mg Se/kg). Stored under standard conditions 
(25 °C and 60 % RH), the recovery of SeMet in mash feed ranged between 97 and 120 % of the 
analysed initial value. One lot of the additive in a pelleted sample showed a comparable stability over 
three months.
33 Data on the stability of SeMet during feed processing were not submitted. 
2.4.2.  Homogeneity  
The  capacity  of  the  additive  to  homogeneously  distribute  in  mash  and  pelleted  feed  (unknown 
composition) was studied by analysing ten samples of each of the different feed types.
34 An average 
content of 0.596 mg SeMet/kg in mash feed and 0.748 mg SeMet/kg in pelleted feed was found. The 
coefficients of variation were 9.1 and 11.7 % for mash and pelleted feed, respectively. 
Homogeneity tests were conducted with the product in its initial formulation. The FEEDAP Panel 
cannot exclude the possibility that the change of product formulation (leading to a higher particle size) 
may have an impact on the homogeneity; however, no new data were submitted. 
2.5.  Physico-chemical incompatibilities in feed  
Based on current knowledge, under practical use conditions, no incompatibilities between DL-SeMet 
and feed materials, carriers, other approved additives, or medicinal products are expected. 
                                                       
27 Technical Dossier/Section II/ Annex_II_2_1; Technical Dossier/Supplementary information/Annex_II_2_1_1 
28   This section has been edited following the confidentiality claims made by the applicant. 
29 Technical Dossier/Section II/ Annex_II_3_1_1 
30 Technical Dossier/Section II/ Annex_II_3_2_1 
31 Technical Dossier/Supplementary information/Annex II_4_1_1 
32 Technical Dossier/Supplementary information/Annex II_4_1_2 
33 Technical Dossier/Supplementary information/Annex II_4_1_3 
34 Technical Dossier/Section II/ Annex_II_4_2_1 DL-Selenomethionine for all species 
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2.6.  Conditions of use  
The additive is intended to be used in all animal species and categories as a source of selenium. Total 
selenium in complete feed should not exceed 0.5 mg/kg.
35 
2.7.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of selenium from 
DL-SeMet from Mintrex
®Se in animal feed. The executive summary of the EURL report can be found 
in the Appendix. 
3.  Safety 
3.1.  Safety for the target species  
3.1.1.  Tolerance study 
A combined tolerance/efficacy study with DL-SeMet was performed on a total of 672 one-day-old 
chickens for fattening (Ross 308, equal number of each sex, 40 g initial body weight) for 38 days.
36 
The birds were allocated to eight treatments (84 chickens per treatment): a basal diet without selenium 
supplementation (control, 0.04 mg Se/kg feed); the basal diet supplemented with 0.3 mg Se/kg from 
sodium selenite (positive inorganic (IO) control); the basal diet supplemented with 0.3 mg Se/kg from 
a selenised yeast-based additive (positive organic (O) control); and the basal diet supplemented with 
0.1, 0.3, 0.6, 0.9 and 1.5 mg Se/kg from  DL-SeMet (treatment codes: SeMet-0.1 to SeMet-1.5). A 
starter diet was fed for the first 21 days followed by a grower feed until completion. Both diet types, 
fed in mash form ad libitum, consisted mainly of corn, soybean meal and soy oil. The starter feed was 
calculated to contain 21.5 % crude protein (CP) and 11.89 MJ metabolisable energy (ME)/kg, the 
grower  20.5 %  CP  and  12.60  MJ  ME/kg.  The  diets  were  analysed  for  nutritional  homogeneity 
(confirmed by proximate analysis), and selenium. Group size was six male and six female pens with 
seven birds per pen. The birds were allocated at random to the pens,  and the pens by a random 
complete block design to the treatments. 
Zootechnical parameters
37 were measured on day 36. On day 37, blood samples from one bird per pen 
were taken for routine haematology   and  clinical biochemistry,
38  analysis of plasma  selenium  and 
plasma glutathione peroxidase (GSH-Px); liver samples also from one bird per pen were analysed for 
GSH-Px. On day 38, samples of tissues (liver, kidney, muscle, skin/fat) were taken from one bird per 
pen for determination of selenium concentration (except groups SeMet-0.9 and SeMet-1.5). Necropsy 
(with particular attention to crop, proventriculus, gizzard, small intestine, caeca, large intestine, liver, 
kidney, lung, spleen, heart, bone (tibia) and feet) was performed on  another two birds from each pen. 
Analysis of  selenium  in feed and tissues was  carried  out  by  inductively coupled plasma mass 
spectrometry (ICP-MS) (validated internal method). 
Data were subjected to factorial analysis of variance (ANOVA) to examine the main effect of dietary 
treatment, sex and their interactions using the generalised linear model (GLM) procedure of SAS. The 
pen was the experimental unit. 
The results relevant for assessing the tolerance of chickens for fattening to  DL-SeMet are summarised 
in  Table  2.  Overall  mortality  (including  culling)  was  very  low  (0.89 %).  No  significant  effect  of 
treatment on any of the zootechnical parameters assessed could be detected when analysing male and 
female broilers together. However, a significant interaction effect between dietary treatment and sex 
                                                       
35 In recent regulations, the EC has limited the supplementation to feed from other organic sources of selenium to 0.2 mg 
  Se/kg (see footnote 11).  
36 Technical Dossier/Section III/Annex_III_1_1_1. 
37 Average daily weight gain, average feed intake and feed to gain ratio. 
38   Total  blood  cell  count,  white  blood  cell  count,  haemoglobin,   haematocrit,  aspartate  aminotransferase,  alanine 
  aminotransferase, gamma glutamyl transferase, glucose, uric acid, albumin, total protein. DL-Selenomethionine for all species 
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was detected for some parameters. Male chickens of the SeMet-0.1 group gained significantly more 
weight than male broilers of the SeMet-0.6 group. Additionally, male broilers of the SeMet-1.5 group 
tended to gain more weight than male broilers of the SeMet-0.6 group (P= 0.052). Dietary treatments 
did not have a significant effect on the performance of female broilers. 
Table 2:   Zootechnical data (36 days), plasma Se and GSH-Px in plasma and liver, haematology and 
biochemistry endpoints with significant differences in chickens for fattening (37 days) 
Code 
Control  IO 
Control  O Control  SeMet-0.1  SeMet-0.3  SeMet-0.6  SeMet-0.9  SeMet-1.5 
Se source  none  Na2SeO3  Se-Yeast  DL-SeMet 
Se supplemented (mg/kg)  0  0.3  0.3  0.1  0.3  0.6  0.9  1.5 
Se analysed                 
- starter (mg/kg)  0.035  0.302  0.328  0.167  0.373  0.737  0.994  1.675 
- grower (mg/kg)  0.046  0.303  0.390  0.139  0.353  0.653  0.929  1.760 
Mortality (%)  0.0  0.0  0.0  2.4  0.0  1.2  2.4  1.2 
Body weight (g)  1643  1664  1660  1713  1685  1628  1706  1711 
Feed intake (g/day)  70  70  70  70  70  68  71  71 
Feed/gain  1.58  1.55  1.55  1.55  1.54  1.55  1.54  1.53 
Plasma Se (µg/kg)  41.2
f  136.8
de  153.8
d  93.6
e  184.8
cd  226.8
bc  270.7
b  365.7
a 
Plasma GSH-Px*  n.d.  344.6
a  417.5
a  182.8
b  374.6
a  322.8
ab  334.4
a  443.2
a 
Liver GSH-Px*  317.2
d  554.8
a  514.3
ab  318.8
d  435.3
bc  420.8
c  386.3
cd  431.1
bc 
WBC** (10
9/L)  26.6
ab  32.3
a  26.8
ab  27.4
ab  22.1
ab  20.3
b  16.0
b  20.8
ab 
ALT** (U/L)  31.9
a  27.5
ab  28.7
ab  24.6
ab  29.8
a  22.6
ab  23.4
ab  18.3
b 
γGT** (U/L)  20.7
b  31.6
a  25.6
ab  26.2
ab  27.3
ab  28.4
ab  23.5
ab  20.8
b 
* In nmol NADP/mL per min; n.d.= not detectable. 
** WBC: White blood cells; ALT: Alanine amino transferase; γGT: Gamma-glutamyltransferase. 
a-f: Values with different letter superscripts are significantly different (P< 0.05). 
The  selenium  content  in  plasma  was  significantly  higher  in  all  SeMet  groups  than  in  the 
unsupplemented control group. Plasma selenium concentration in the SeMet groups showed a dose 
dependent increase. There was no statistically significant difference between the SeMet-0.3 group and 
the IO and O control groups fed diets with the same level of selenium supplementation (0.3 mg/kg) but 
different  selenium  sources  (DL-SeMet,  sodium  selenite,  selenium  enriched  yeast).  However,  a 
tendency for higher plasma selenium could be seen in the SeMet-0.3 group compared with the IO 
control (P= 0.084). No significant interaction between sex and treatment was observed. Plasma GSH-
Px in the control group was below the detection limit. It increased significantly from 182.8 nmol/mL 
per min in the SeMet-0.1 group to 374.6 in the SeMet-0.3 group. This value was not significantly 
different from that in the IO and O control groups and the groups with higher SeMet supplementation. 
The highest liver GSP-Px activity were found in the IO and O control groups; liver GSH-Px activity in 
the groups fed 0.3, 0.6, 0.9 and 1.5 mg supplemented selenium from SeMet was not different from 
each other. 
Considering haematology, statistically significant differences among treatments were found in white 
blood cell counts (WBC) but not for the other parameters (total blood cell counts (2.6 2.7 x 10
12/L), 
haemoglobin (6.4 6.9 mmol/L) and haematocrit (28.9 31.4 %)). WBCs were significantly higher in 
broilers of the IO control than broilers of the SeMet-0.6 and SeMet-0.9 groups and tended to be higher 
than in  the  SeMet-1.5.  Despite these  few  significant  differences in  WBC, the  values  found  were 
considered to lie within the physiological range for broilers. 
Considering clinical biochemistry, statistically significant differences among treatments were found 
for alanine amino transferase (ALT) and gamma-glutamyltransferase (γGT) in blood, but not for the 
other  endpoints  (aspartate  aminotransferase  (AST)  (213 232  U/L),  total  protein  (35.4 38.3  g/L), 
albumin (26.9 27.9 g/L), glucose (9.1 10.7 mmol/L), and uric acid (6.1 8.2 mg/dL)). The control and 
the SeMet-0.3 groups showed a significantly higher ALT value than birds of the SeMet.-1.5 group. DL-Selenomethionine for all species 
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Additionally, birds of the IO group had significantly higher γGT activities compared to control and 
SeMet-1.5 birds. The ALT and γGT values were all within the physiological range considering the 
routine laboratory method applied. Although some significant differences in ALT and γGT activity in 
plasma  were  observed,  no  treatment  related  effect  (neither  selenium  source  nor  level)  could  be 
derived. 
At necropsy, liver discoloration (pale) was found in one liver in each of the SeMet-0.3, SeMet-0.6 and 
SeMet-1.5 groups; heart lesions were found in two animals in each of the control and the IO control 
groups and one animal in each of the SeMet-0.1, SeMet-0.3, SeMet-0.9 and SeMet-1.5 groups. No 
other significant lesions were reported. Considering the low rate of occurrence of lesions, and that are 
not  exceptional  for  a  normal  healthy  broiler  population,  the  FEEDAP  Panel  concludes  that  no 
treatment-related alterations of the digestive tract, the organs and the skeleton were found. 
The results of the tissue deposition study are described in Table 3. 
Table 3:     Selenium content in liver, kidney, muscle and skin/fat (µg Se/kg fresh tissue) in chickens 
for fattening (38 days) 
Code 
Control  IO Control  O Control  SeMet-0.1  SeMet-0.3  SeMet-0.6 
Se source  none  Na2SeO3  Se-yeast  DL-SeMet 
Se supplemented (mg/kg)  0  0.3  0.3  0.1  0.3  0.6 
Se analysed             
- starter (mg/kg)  0.035  0.302  0.328  0.167  0.373  0.737 
- grower (mg/kg)  0.046  0.303  0.390  0.139  0.353  0.653 
Liver (µg/kg)  78
e  460
c  513
c  309
d  626
b  842
a 
Kidney (µg/kg)  148
e  624
c  574
c  438
d  755
b  941
a 
Muscle (µg/kg)  27
e  82
d  156
c  133
c  357
b  607
a 
Skin/fat (µg/kg)  33
e  145
c  159
bc  101
d  184
b  316
a 
a-e: Values with different letter superscripts are significantly different (P< 0.05). 
A significant dose-related response of selenium deposition to dietary selenium was observed in all 
tissues examined in the SeMet-0.1, SeMet-0.3, and SeMet-0.6 groups. The selenium concentration of 
all tissues in animals of the SeMet-0.1 group (0.1 mg selenium supplementation from DL-SeMet per kg 
feed)  was  significantly  higher  than  in  the  unsupplemented  control  group.  A  significantly  higher 
selenium content was also observed in liver, kidney, muscle and skin/fat of the SeMet-0.3 group than 
in the IO group (supplemented with the same amount of selenium, but from Na2SeO3) and except 
skin/fat,  also  in  the  O-control  group  (supplemented  with  Se-yeast).  There  was  no  significant 
interaction between sex and treatment.  
The contribution of the DL-SeMet in terms of methionine as an amino acid added to feed would be 
negligible considering the limits set by the EU for total selenium in feed. 
3.1.2.  Conclusions on the safety for target species 
Selenium  from  DL-SeMet  was  tolerated  by  chickens  for  fattening  at  up  to  1.5  mg  supplemented 
level/kg feed; DL-SeMet is therefore safe for chickens for fattening provided total dietary selenium 
does not exceed 0.5 mg/kg complete feed. The FEEDAP Panel extends this conclusion to all animal 
species. DL-Selenomethionine for all species 
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3.2.  Safety for the consumer  
3.2.1.  Metabolic and residues studies 
SeMet from organic selenocompounds can be incorporated nonspecifically into normal body proteins 
such as albumin and haemoglobin (Hb) in place of methionine. SeMet in body proteins is stored non-
functionally but may later be released by catabolism, and then be converted to hydrogen selenide. 
Alternatively SeMet can be trans-selenated to selenocysteine (SeCys), which is then also converted to 
hydrogen  selenide  (Rayman,  2004;  Rayman  et  al.,  2008).  Selenide  is  an  intermediate  compound; 
which  is  utilized  in  the  synthesis  of  selenoenzymes,  transformed  into  methylated  metabolites  for 
excretion, as well as oxidised to selenium dioxide, a pathway associated with toxicity, owing to the 
production of superoxide and other reactive oxygen species (Suzuki et al 2006; Rayman et al., 2008). 
The uptake of SeMet in brush border membrane vesicles from rats showed a linear  relationship with 
concentration,  whereas  selenite  showed  a  curvilinear  relationship  (Vendeland  et  al.,  1994).  In 
weanling rats fed levels of 0.2 4.0 mg DL-SeMet/kg feed for nine weeks, selenium deposition in liver, 
muscle and brain was significantly higher than in animals expose to analogous dietary concentrations 
of selenium from sodium selenite (Deagen et al., 1987). In humans supplemented with SeMet, plasma 
selenium increased more rapidly and retention (as measured by urine excretion) was higher than with 
other sources: retentions of SeMet was reflected in blood selenium levels (Robinson et al., 1978).  
Concerning  the  racemic  mixture  (DL-SeMet),  after  its  absorption  in  the  gastrointestinal  tract  of 
animals, part of the SeMet is metabolised to dihydrogen selenide to be utilised in selenium pathways, 
whereas another portion is non-specifically incorporated into body proteins as a substitute  for the 
common amino acid methionine (Schrauzer, 2000). The D-enantiomer, when absorbed, is converted 
into the L-enantiomer (Lewis and Baker, 1995), and consequently only L-SeMet is incorporated in the 
protein of tissues and animal products. 
In the combined tolerance/efficacy study submitted by the applicant (for protocol description, see 
section 3.1.1), the results obtained for selenium deposition in tissues (liver, kidney, muscle, skin/fat) 
showed  a  similar  pattern  for  DL-SeMet  as  for  Se-yeast  (Table  3),  demonstrating  that  selenium 
deposition from DL-SeMet is significantly higher than from sodium selenite.  
3.2.2.  Toxicological studies 
The EFSA‟s Panel on Food Additives and Nutrient Sources added to Food reviewed the toxicological 
studies of L-SeMet (EFSA, 2009b) and concluded that the toxicity of L-SeMet is comparable to that of 
other forms of selenium, in terms of equivalent amounts of bioavailable selenium. The applicant has 
provided two further genotoxicity studies conducted with the DL-SeMet  under assessment. 
The mutagenic activity of the test item DL-selenomethionine  was assessed by means of the Ames test 
in the five standard Salmonella Typhimurium strains (TA1535, TA1537, TA98, TA100 and TA102) 
tested either in presence or in absence of metabolic activation (S9 mix), in two independent assays, 
following a preliminary concentration-finding assay; owing to strong toxicity, the resulting highest 
tested concentrations were rather low (20 to 200 μg/plate).
39 Under the test conditions, no mutagenic 
activity was revealed. 
In an in vitro mammalian cell micronucleus test on TK6 lymphoblastoid human cells, cells were 
treated in presence and in absence of metabolic activation (S9 mix), either with a short (3 hours) or 
prolonged (27 hours) treatment.
40 DL-SeMet induced statistically significant increases in the number of 
micronucleated cells both with and without metabolic activation upon 3-hour treatment, and with 
metabolic activation only upon the prolonged treatment. 
                                                       
39 Technical Dossier/Section III/ Annex_III_2_2_2_1. 
40 Technical Dossier/Section III/ Annex_III_2_2_2_2. DL-Selenomethionine for all species 
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The FEEDAP Panel considers that the potential to elicit genotoxic effects in vitro is consistent with 
other findings on different selenocompounds indicating DNA damage that may be subsequent to the 
formation of DNA reactive oxygen radicals by means of a threshold mechanism; this view is in line 
with that expressed by the Scientific Committee on Food (EC, 2000). 
Based  on  available  toxicity  studies  and  previous  assessments  on  closely  related  compounds,  the 
FEEDAP  Panel  concludes  that  selenium  from  DL-SeMet  does  not  elicit  any  adverse  effects  not 
expected in a selenium compound. 
3.2.3.  Assessment of safety for consumers 
The upper tolerable level (UL) for selenium has been set by the Scientific Committee on Food (EC, 
2000)  (adults:  300  μg/day;  toddlers:  60  μg/day),  and  used  by  the  FEEDAP  Panel  in  previous 
assessments of the consumer safety for different selenium compounds. 
The FEEDAP Panel has several times expressed its view that all SeMet sources would result in similar 
selenium deposition (EFSA 2011a, b, 2012a); this view was later extended to the hydroxy-analogue of 
SeMet (HMSeBA) (EFSA FEEDAP Panel, 2013a) and to L-SeMet (EFSA FEEDAP Panel, 2013b). 
There is no reason to assume that SeMet from different sources would result in an essentially different 
deposition pattern in edible tissues/products. This view is supported by data provided by the applicant 
that showed increased tissue deposition of selenium from DL-SeMet compared with sodium selenite 
(see Table 3).  
The FEEDAP Panel has previously concluded that the selenium supplementation of feed by selenised 
yeast, by HMSeBA or by L-SeMet should be limited to a maximum of 0.2 mg Se/kg feed. Therefore 
with respect to  consumer safety,  the  Panel  concludes  that  supplemental  selenium  from  DL-SeMet 
should be limited to a maximum of 0.2 mg/kg feed. 
3.3.  Safety for the users/workers  
3.3.1.  Effects on the respiratory system 
The applicant provided data on a DL-SeMet containing additive which did not release any measurable 
dust in a Stauber-Heubach system. Consequently, there will be no inhalation exposure to DL-SeMet of 
users/workers. However, as long as the additive is not the subject of authorisation and considering the 
high toxicity of selenium, it would be prudent to consider DL-SeMet as a hazard by inhalation which 
requires protection measures.  
3.3.2.  Effects on eyes and skin  
Acute eye irritation of the formulated additive (0.5 % DL-SeMet) was studied following a single ocular 
instillation in rabbits in accordance with OECD Guideline 405.
41 Three animals were used for the 
study. A dose of 0.1 g of test item was introduced into the conjunctival s ac of the left eye of each of 
the animals. The untreated right eye served as a control. Any conjunctival, iris and corneal changes 
were evaluated approximately one hour, 24 hours, 48 hours, 72 hours after instillation. The application 
of the test item did not induce ocular changes. 
Skin irritation was tested  in rabbits following a single, semi-occluded application to intact skin in 
accordance with OECD Guideline 404.
42 Three animals were used for the study. A dose of 0.5 g of the 
formulated additive  (0.5 % DL-SeMet) was applied to the skin. Semi-occlusive dressings held the test 
item in place for 3 minutes, 1 hour and 4 hours on the skin of the first animal and for 4 hours for the 
two other animals. Any cutaneous lesion was evaluated approximately one hour, 24, 48 and 72 hours 
after removal of the dressing. The application of the test item did not induce skin lesions.  
                                                       
41 Technical Dossier/Section III/Annex III_3_1_2_2. 
42 Technical Dossier/Section III/Annex III_3_1_2_1. DL-Selenomethionine for all species 
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The formulated additive (0.5 % DL-SeMet) was tested for skin sensitising potential (using the Buehler 
test) in guinea pigs in accordance with OECD Guideline 406.
43 The extent and degree of skin reaction 
to a challenge exposure at a non irritant dose on day 29, following previous topical exposure (at days 
1, 8 and 15) in a near-to-irritant dose (0.5 g) was measured in ten male and ten female guinea pigs. No 
allergic reaction was induced in any of the treated animals. 
3.3.3.  Conclusion on the safety for the users/workers 
Although a DL-SeMet containing additive did not release any measurable dust, it would be prudent to 
consider the additive as a hazard by inhalation, which requires protection measures since the additive 
is not the subject of authorisation, and selenium is highly toxic. The additive is not an irritant to skin 
and eyes and is not a dermal sensitiser. 
3.4.  Safety for the environment  
There is no information suggesting that selenium, when provided to animals as DL-SeMet, would be 
more  harmful  to  the  environment  than  selenium  from  other  sources  already  authorised  as  feed 
additives.
44 It is well documented in the scientific literature that, owing to the  specific metabolic fate 
of  DL-SeMet,  significantly  more  selenium  from  organic  sources  than  from  inorganic  sources  is 
retained in the animal body. 
Therefore, the FEEDAP Panel considers that the use of DL-SeMet in feed does not pose an additional 
risk to the environment, compared with other sources of selenium for which it will substitute, as long 
as the maximum authorised content in complete feed is not exceeded. 
4.  Efficacy  
Evidence of in vivo bioavailability can be taken to support efficacy for compounds of essential trace 
elements. One trial in a single animal species, including laboratory animals, is considered sufficient 
(EFSA, 2012b). As already established in previous opinions of the FEEDAP Panel (e.g. EFSA 2006a, 
b,  2009a,  2011a,  2012a),  the  bioavailability  of  a  source  of  selenium  as  nutritional  additive  is 
considered to  be  demonstrated  if  one  of  the  specific  endpoints (glutathione peroxidase  (GSH-Px) 
activity in plasma or whole blood, selenium concentration in plasma/serum or whole blood, selenium 
content in liver) is significantly influenced by the test item. Tissue deposition of selenium from the 
selenocompound SeMet is considered to reflect directly only the unspecific incorporation of Se-Met 
into general body proteins (EFSA, 2006a).  
The applicant provided two long-term efficacy studies in chickens for fattening, carried out at two 
different locations. 
4.1.  Studies in chickens for fattening 
 
The first study provided is a combined tolerance/efficacy trial which has already been described in 
Section 3.1.1. The zootechnical data did not show any difference among the treatments (see Table 2). 
The  data  clearly  indicate  that  selenium  from  DL-SeMet  is  absorbed  (see  plasma  selenium 
concentrations in Table 2), used in the synthesis of selenium-specific enzyme (see GSH-Px in plasma 
in Table 2) and deposited in edible tissues (see Table 3). 
A second study was carried out with a total of 576 one-day old chicks (Ross 308, males), allocated to 
nine treatments (eight pens of eight broilers/treatment).
45 Five groups were relevant for the assessment 
of the  DL-SeMet  efficacy  as  a  source  of  selenium  in  chickens:  a  control  group  fed  a  selenium 
unsupplemented diet (0.23 mg Se/kg), two groups with supplemental 0.15 mg Se/kg and 0.30 mg 
                                                       
43 Technical Dossier/Section III/Annex III_3_1_2_3. 
44 Inorganic selenium: sodium selenite and sodium selenate. Organic selenium: selenium produced by the selenium-enriched 
yeasts Saccharomyces cerevisiae CNCM I-3060, S. cerevisiae NCYC R397, S. cerevisiae CNCM I-3399, S. cerevisiae 
NCYC R645 and S. cerevisiae NCYC R646; hydroxy-analogue of selenomethionine; L-selenomethionine. 
45 Technical Dossier/Section IV/Annex_III_2_1_2_1. DL-Selenomethionine for all species 
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Se/kg from DL-SeMet and sodium selenite, respectively. Mortality within 35 days was low (3.6 %) and 
not treatment related. The zootechnical parameters, measured at 27 days, did not significantly differ 
between the groups. GSH-Px in plasma and liver (at day 28) was also not affected by the treatments. 
The only difference found was in the selenium concentration in liver (day 35) showing a significant 
higher  concentration  for  the  DL-SeMet  group  supplemented  with  0.3  mg  Se/kg  than  in  the 
unsupplemented control group (640 vs. 519 µg Se/kg liver).  
4.2.  Efficacy in ruminants 
In a previous opinion (EFSA FEEDAP Panel, 2013b), the FEEDAP Panel provided a brief review on 
the  efficacy  of  free  SeMet  in  ruminants,  considering  its  degradation/incorporation  by/into  rumen 
microbiota. Based on the outcome described in the said opinion, the Panel concludes that DL-SeMet 
would be utilised in ruminants as a selenium source. 
4.3.  Quality of edible tissues and products 
No study on the influence of the DL-SeMet on the physico-chemical properties or sensory quality of 
edible tissues and products was provided by the applicant. However, one study performed in chickens 
for fattening with L- and D-SeMet supplemented diets, which examined total antioxidant capability in 
kidney, pancreas, and breast muscle, malondialdehyde concentration in kidney and breast muscle and 
drip loss, did not indicate any adverse effect on the quality of edible tissues (Wang et al., 2011). It is 
concluded that the findings for L- and D-SeMet could be extrapolated to DL-SeMet. 
4.4.  Conclusions on efficacy 
Sufficient  evidence that  DL-SeMet  is  an effective  source  of  selenium  in  chickens  for  fattening  is 
provided  by  one  study.  A  second  study  in  the  same  species  failed  to  reach  the  same  degree  of 
evidence, most probably because of the already high level of selenium in the control diet. Since there 
are no fundamental differences between target animals in the metabolism of SeMet and its use for the 
specific selenium biological functions, the FEEDAP Panel extends its conclusion on the efficacy of 
DL-SeMet to all animal species and categories. It is not expected that the use of DL-SeMet in animal 
nutrition would negatively affect the quality of edible tissues and products. 
5.  Post-market monitoring  
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
46  and  Good 
Manufacturing Practice. 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
Selenium from DL-SeMet was tolerated by chickens for fattening at up to 1.5 mg supplemental level; 
DL-SeMet is therefore safe for chickens for fattening provided total dietary selenium does not exceed 
0.5 mg/kg complete feed. The FEEDAP Panel extends this conclusion to all animal species. 
Based  on  available  toxicity  studies  and  previous  assessments  on  closely  related  compounds,  the 
FEEDAP  Panel  concludes  that  selenium  from  DL-SeMet  does  not  elicit  any  adverse  effects  not 
expected in a selenium compound. The use of DL-SeMet in animal nutrition is expected to result in a 
similar increase in selenium deposition in animal tissues/products as that resulting from other sources 
of SeMet. To ensure consumer safety from consumption of food originating from animals fed  DL-
SeMet, the FEEDAP Panel concludes that dietary selenium supplementation from the additive should 
not exceed a maximum of 0.2 mg/kg complete feed. 
                                                       
46   Regulation  (EC)  No  183/2005  of  the  European  Parliament  and  of  the  Council  of  12  January  2005  laying  down 
  requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1. DL-Selenomethionine for all species 
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Although  a  DL-SeMet  containing  additive  did  not  release  any  measurable  dust,  the  additive  is 
considered as a hazard by inhalation, which requires protection measures for users since the additive is 
not the subject of authorisation, and selenium is highly toxic. The additive is not an irritant to skin and 
eyes and is not a dermal sensitiser. 
The use of DL-SeMet in feed does not pose an additional risk to the environment, compared with other 
sources  of  selenium  for  which  it  will  substitute,  as  long  as  the  maximum  authorised  content  in 
complete feed is not exceeded. 
Sufficient  evidence is provided  that  DL-SeMet  is  an  effective  source  of  selenium  in  chickens for 
fattening. Since there are no fundamental differences between target animals in the metabolism of 
SeMet and its use for the specific biological functions of selenium, the FEEDAP Panel extends its 
conclusion on the efficacy of DL-SeMet to all animal species and categories.  
RECOMMENDATIONS 
The “Description and conditions of use of the additive” should refer to the selenium compound and its 
selenium content. The additive should be incorporated into complete feed via premixtures only. 
The FEEDAP Panel strongly recommends that DL-SeMet should be placed on the market only in a 
formulation with reduced selenium content and low dusting potential (as described in the application 
by 2000 mg Se/kg additive and no measurable dusting potential). 
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APPENDIX  
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed Additives on the Method(s) of Analysis for DL-Selenomethionine
47 
In  the  current  application  authorisation  is  sought  under  article  4(1)  for  Mintrex
®Se  (DL-
Selenomethionine)  under  the  category/functional  group  3(b)  „nutritional  additives‟/„compounds  of 
trace elements‟ according to the classification system of Regulation (EC) No 1831/2003. Specifically, 
authorisation is sought for the use of the feed additive for all animal species and categories. 
The  active  substance  of  the  product  is  DL-Selenomethionine,  produced  by  chemical  synthesis. 
Mintrex®Se is a white to tan powder preparation consisting of 0.5 % of DL-Selenomethionine, which 
corresponds to 0.2 % of selenium; 0.5 % of mineral oil and 99 % of calcium carbonate carrier. 
The feed additive is intended to be incorporated into feedingstuffs through premixtures, to obtain a 
maximum total selenium dosage of 0.5 mg/kg feedingstuffs thus complying with legal requirements; 
no minimum dose was proposed by the Applicant. 
For the determination of DL-Selenomethionine in the feed additive and in feedingstuffs the Applicant 
submitted two single laboratory validated and further verified methods based on high performance 
liquid chromatography with UV detection (HPLC-UV) for feed additive samples; and based on high 
performance liquid chromatography inductively coupled plasma mass spectrometry (HPLC-ICP-MS) 
for feedingstuffs samples. 
For the determination of total selenium in the feed additive the Applicant submitted a single laboratory 
validated and further verified method based on microwave digestion with nitric acid and hydrogen 
peroxide  (HNO3/H2O2)  followed  by  inductively  coupled  plasma  mass  spectrometry  (ICP-MS). 
Furthermore,  an  alternative  single-laboratory  validated  and  further  verified  method  based  on 
inductively coupled plasma atomic emission spectrometry (ICPAES) was previously evaluated and 
recommended by the EURL for the determination of total selenium in the feed additives (cf. FAD-
2009-0010; FAD-2011-0028 and FAD-2011-0044). 
For the determination of total selenium in feedingstuffs the Applicant applied the abovementioned 
ICP-MS method. The EURL identified instead for the determination of total selenium in feedingstuffs 
the  CEN  method  EN 16159:2012  based  on  Hydride  Generation  Atomic  Absorption  Spectrometry 
(HGAAS) after microwave digestion with HNO3/H2O2. For the determination of total selenium in 
premixtures,  the  EURL  suggests  diluting  the  premixtures  samples  with  ground  cereal  feed  and 
applying the abovementioned HGAAS method. 
Based on the performance characteristics presented the EURL recommends for official control the 
single-laboratory validated and further verified methods based on HPLC-UV and ICP-MS or ICP-AES 
for the determination of DL-Selenomethionine and total selenium in the feed additive, respectively. As 
for the determination of total selenium in premixtures and feedingstuffs, the EURL recommends the 
ring-trial validated CEN method, based on HGAAS (EN 16159:2012). 
Even though the performance characteristics of the HPLC-ICP-MS method for the determination of 
DL-Selenomethionine in feedingstuffs are acceptable, the EURL will not recommend this method since 
no limits for Selenomethionine in feedingstuffs are included in the proposed Register Entry and the 
HPLC-ICP-MS  equipment  required  for  analysis  is  not  readily  available  in  all  official  control 
laboratories. 
                                                       
47   The full report is available on the EURL website: http://irmm.jrc.ec.europa.eu/SiteCollectionDocuments/FinRep-FAD-
2012-0042-DL-MetSe.doc.pdf DL-Selenomethionine for all species 
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Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 